Merck

M0370020

甲哌卡因杂质B

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

别名:
Desbutylbupivacaine, (RS)-N-(2,6-Dimethylphenyl)piperidine-2-carboxamide
经验公式(希尔记法):
C14H20N2O
CAS号:
分子量:
232.32
MDL编号:
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

mepivacaine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

O=C(NC1=C(C)C=CC=C1C)C2NCCCC2

InChI

1S/C14H20N2O/c1-10-6-5-7-11(2)13(10)16-14(17)12-8-3-4-9-15-12/h5-7,12,15H,3-4,8-9H2,1-2H3,(H,16,17)

InChI key

SILRCGDPZGQJOQ-UHFFFAOYSA-N

正在寻找类似产品? Visit 产品对比指南

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品
Y0000089Y0000088P2939025
甲哌卡因杂质B European Pharmacopoeia (EP) Reference Standard

M0370020

甲哌卡因杂质B

vibrant-m

Y0000089

布比卡因杂质E

vibrant-m

Y0000088

布比卡因杂质B

vibrant-m

P2939025

Prilocaine impurity E

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

neat

format

neat

API family

mepivacaine

API family

bupivacaine

API family

bupivacaine

API family

prilocaine

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Mepivacaine impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbones

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

为方便起见,与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

M Gantenbein et al.
The Journal of pharmacy and pharmacology, 49(3), 293-295 (1997-03-01)
Previous workers have reported that 0.01 mg kg-1 of levcromakalim injected intraperitoneally did not modify bupivacaine-induced neurotoxicity but increased the duration of action of bupivacaine. This study was designed to document possible changes in the pharmacokinetic behaviour of bupivacaine and
B Bruguerolle et al.
Clinical and experimental pharmacology & physiology, 21(12), 997-999 (1994-12-01)
1. This study was designed to document the acute toxicity of two metabolites of bupivacaine, desbutylbupivacaine (2,6, desbutylbupivacaine; PPX) and pipecolic acid in mice. All the compounds were administered by the intraperitoneal (i.p.) route. 2. The mean convulsant activity was
Mika J Jokinen et al.
European journal of clinical pharmacology, 58(10), 653-657 (2003-03-01)
To assess the effect of ciprofloxacin on the pharmacokinetics of ropivacaine. METHODS. In a double-blind, randomised, cross-over study, nine healthy volunteers were treated for 2.5 days with 500 mg oral ciprofloxacin or placebo twice daily. On day 3, they received
Robin Ledger
Journal of biochemical and biophysical methods, 57(2), 105-114 (2003-08-14)
Less than 11% of the dose of bupivacaine could be accounted for in urine from 10 patients receiving continuous epidural infusions. HPLC analysis of metabolites confirmed (S)-bupivacaine was more extensively metabolised than (R)-bupivacaine, and dealkylation was the predominant metabolic pathway
L Aarons et al.
British journal of anaesthesia, 107(3), 409-424 (2011-06-23)
The aim was to characterize ropivacaine and 2',6'-pipecoloxylidide (PPX) pharmacokinetics and factors affecting them in paediatric anaesthesia. Population pharmacokinetics of ropivacaine and its active metabolite PPX were estimated after single and continuous ropivacaine blocks in 192 patients aged 0-12 yr

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门